Skip to main content
. 2011 Mar;3(2):73–83. doi: 10.1177/1758834010392445

Table 1.

Case series of women (n > 20) with breast cancer receiving chemotherapy during pregnancy.

Study Number of patients Regimen Gestational age at starting chemotherapy Gestational age at delivery Birth weight Congenital anomalies
Cardonick et al. [2010] 130 AC (69%), FAC, FEC, A single agent, V single agent taxane also given in 11 cases Mean 20.4 ± 5.4 wks Mean 35.8 ± 1.9 wks Mean 2836 ±  1075 g Four cases (3.8%): – pyloric stenosis – asymptomatic  pulmonary  artery  fistula – holoprosencephalopathy – talipes and  haemangioma
Hahn et al. [2006] 57 FAC Median 23 wks (range 11–34) Median 37 wks (range 29–42) Median 2890 g (range 1389–3977) Three cases (5.3%): – Down’s  syndrome – ureteral  reflux – club foot
Peccatori et al. [2009] 20 Weekly epirubicin 35 mg/m2 Median 19 wks (range, 16–30) Median 35 wks (range, 28–40) Not published One case (5%): – polycystic  kidney
Azim et al. [2008] 26 Anthracycline- based (E = 23, A = 3) Second trimester in all patients Median 35 wks (28–40) Not published One case (3.8%): – polycystic  kidney
Ring et al. [2005b] 28 AC (N = 11), EC (N = 5), CMF (N = 12) Median 20 wks (range 15–33) Median 37 wks (range, 30–40) Median 3000 g (range 1400–3500) Nil

A, adriamycin; C, cyclophosphamide; F, 5-flurouracil; E, epirubicin; V, vinorelbine; M, methotrexate; wks, weeks.